CO2020000194A2 - Inhibidores de quinasa alk2 que contienen imidazol - Google Patents
Inhibidores de quinasa alk2 que contienen imidazolInfo
- Publication number
- CO2020000194A2 CO2020000194A2 CONC2020/0000194A CO2020000194A CO2020000194A2 CO 2020000194 A2 CO2020000194 A2 CO 2020000194A2 CO 2020000194 A CO2020000194 A CO 2020000194A CO 2020000194 A2 CO2020000194 A2 CO 2020000194A2
- Authority
- CO
- Colombia
- Prior art keywords
- kinase inhibitors
- compounds
- inhibitors containing
- containing imidazole
- alk2 kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen compuestos de la Fórmula I, II, III y IV, y sales de estos aceptables desde el punto de vista farmacéutico. Los compuestos son inhibidores de quinasa ALK2. También se proporcionan composiciones farmacéuticas que comprenden un compuesto de la Fórmula I, II, III o IV, o una sal de este aceptable desde el punto de vista farmacéutico, y métodos que incluyen el uso de los compuestos, o sales de estos aceptables desde el punto de vista farmacéutico, y de las composiciones en el tratamiento y la prevención de distintas enfermedades y afecciones, tales como fibrodisplasia osificante progresiva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762520150P | 2017-06-15 | 2017-06-15 | |
PCT/US2018/037503 WO2018232094A1 (en) | 2017-06-15 | 2018-06-14 | Imidazole-containing inhibitors of alk2 kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020000194A2 true CO2020000194A2 (es) | 2020-04-24 |
Family
ID=64659499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0000194A CO2020000194A2 (es) | 2017-06-15 | 2020-01-09 | Inhibidores de quinasa alk2 que contienen imidazol |
Country Status (18)
Country | Link |
---|---|
US (2) | US11661426B2 (es) |
EP (1) | EP3638229A4 (es) |
JP (2) | JP7257338B2 (es) |
KR (1) | KR102659955B1 (es) |
CN (1) | CN110913855A (es) |
AR (1) | AR112027A1 (es) |
AU (2) | AU2018283053C1 (es) |
BR (1) | BR112019026517A2 (es) |
CA (1) | CA3066164A1 (es) |
CL (1) | CL2019003669A1 (es) |
CO (1) | CO2020000194A2 (es) |
EA (1) | EA202090052A1 (es) |
IL (1) | IL271109A (es) |
MA (1) | MA49401A (es) |
MX (2) | MX2019015226A (es) |
PH (1) | PH12019502781A1 (es) |
SG (1) | SG10202112496SA (es) |
WO (1) | WO2018232094A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2970205T (pt) | 2013-03-14 | 2019-08-26 | Tolero Pharmaceuticals Inc | Inibidores da jak2 e da alk2 e métodos para a sua utilização |
AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物 |
EP3919484B1 (en) * | 2019-01-29 | 2023-05-24 | Shandong Xuanzhu Pharma Co., Ltd. | Hexone glucokinase inhibitor and use thereof |
WO2020235902A1 (ko) * | 2019-05-17 | 2020-11-26 | 주식회사 보로노이 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
EA202193049A1 (ru) * | 2019-05-21 | 2022-02-14 | Вороной Инк. | N-содержащее производное гетероарила и фармацевтическая композиция, содержащая его в качестве активного ингредиента для предупреждения или лечения рака |
GB202006382D0 (en) | 2020-04-30 | 2020-06-17 | Spermatech As | Use |
MX2023007378A (es) * | 2020-12-21 | 2023-07-04 | Biocryst Pharm Inc | Regimenes de dosificacion de inhibidores orales de alk2. |
CA3219966A1 (en) * | 2021-05-25 | 2022-12-01 | Biocryst Pharmaceuticals, Inc. | Imidazole-containing inhibitors of alk2 kinase |
WO2023198114A1 (zh) * | 2022-04-13 | 2023-10-19 | 杭州邦顺制药有限公司 | Alk2激酶抑制剂 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic Inc | Intraluminale prothese mit wirkstoffeluierung. |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US6335324B1 (en) | 1998-06-25 | 2002-01-01 | Bristol-Myers Squibb Co. | Beta lactam compounds and their use as inhibitors of tryptase |
BR0015718A (pt) * | 1999-11-22 | 2002-07-23 | Warner Lambert Co | Quinazolinas e seu uso para inibição de enzimas de cinase dependente de ciclina |
HUP0301236A2 (hu) * | 2000-06-28 | 2003-10-28 | Astrazeneca Ab, | Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként |
CA2422371C (en) | 2000-09-15 | 2010-05-18 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2002336462A1 (en) | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
WO2004081000A1 (en) | 2003-03-10 | 2004-09-23 | Astrazeneca Ab | Quinazoline derivatives |
MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
EP1831216A2 (en) | 2004-12-23 | 2007-09-12 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
JP5185930B2 (ja) * | 2006-07-07 | 2013-04-17 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US20100311965A1 (en) | 2007-12-28 | 2010-12-09 | Carna Biosciences Inc. | 2-aminoquinazoline derivative |
RU2011116928A (ru) | 2008-09-30 | 2012-11-20 | Астразенека Аб (Se) | Гетероциклические ингибиторы jак киназы |
TR201910781T4 (tr) | 2009-06-12 | 2019-08-21 | Abivax | Kanser tedavisi için yararlı bileşikler. |
AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
US9422267B2 (en) | 2012-12-26 | 2016-08-23 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
PT2970205T (pt) * | 2013-03-14 | 2019-08-26 | Tolero Pharmaceuticals Inc | Inibidores da jak2 e da alk2 e métodos para a sua utilização |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
CN108239071B (zh) * | 2016-12-27 | 2020-12-04 | 沈阳药科大学 | 酰胺及硫代酰胺类衍生物及其制备方法和应用 |
AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
-
2018
- 2018-06-13 AR ARP180101628A patent/AR112027A1/es unknown
- 2018-06-14 SG SG10202112496SA patent/SG10202112496SA/en unknown
- 2018-06-14 MA MA049401A patent/MA49401A/fr unknown
- 2018-06-14 US US16/622,816 patent/US11661426B2/en active Active
- 2018-06-14 WO PCT/US2018/037503 patent/WO2018232094A1/en active Application Filing
- 2018-06-14 AU AU2018283053A patent/AU2018283053C1/en active Active
- 2018-06-14 MX MX2019015226A patent/MX2019015226A/es unknown
- 2018-06-14 JP JP2019568599A patent/JP7257338B2/ja active Active
- 2018-06-14 BR BR112019026517-1A patent/BR112019026517A2/pt unknown
- 2018-06-14 EA EA202090052A patent/EA202090052A1/ru unknown
- 2018-06-14 EP EP18816547.6A patent/EP3638229A4/en active Pending
- 2018-06-14 KR KR1020207001054A patent/KR102659955B1/ko active IP Right Grant
- 2018-06-14 CA CA3066164A patent/CA3066164A1/en active Pending
- 2018-06-14 CN CN201880052585.8A patent/CN110913855A/zh active Pending
-
2019
- 2019-12-02 IL IL271109A patent/IL271109A/en unknown
- 2019-12-10 PH PH12019502781A patent/PH12019502781A1/en unknown
- 2019-12-13 CL CL2019003669A patent/CL2019003669A1/es unknown
- 2019-12-13 MX MX2023004309A patent/MX2023004309A/es unknown
-
2020
- 2020-01-09 CO CONC2020/0000194A patent/CO2020000194A2/es unknown
-
2022
- 2022-08-29 AU AU2022221581A patent/AU2022221581A1/en active Pending
-
2023
- 2023-02-13 US US18/168,055 patent/US20230271975A1/en active Pending
- 2023-04-03 JP JP2023060086A patent/JP2023082149A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230271975A1 (en) | 2023-08-31 |
EA202090052A1 (ru) | 2020-05-22 |
JP2023082149A (ja) | 2023-06-13 |
KR102659955B1 (ko) | 2024-04-23 |
TW201904958A (zh) | 2019-02-01 |
MA49401A (fr) | 2020-04-22 |
SG10202112496SA (en) | 2021-12-30 |
MX2019015226A (es) | 2020-08-03 |
PH12019502781A1 (en) | 2020-10-26 |
EP3638229A1 (en) | 2020-04-22 |
JP7257338B2 (ja) | 2023-04-13 |
AR112027A1 (es) | 2019-09-11 |
US11661426B2 (en) | 2023-05-30 |
JP2020523351A (ja) | 2020-08-06 |
CL2019003669A1 (es) | 2020-05-22 |
US20220332723A1 (en) | 2022-10-20 |
AU2018283053A1 (en) | 2020-01-16 |
CN110913855A (zh) | 2020-03-24 |
IL271109A (en) | 2020-01-30 |
AU2022221581A1 (en) | 2022-09-22 |
AU2018283053C1 (en) | 2023-03-02 |
BR112019026517A2 (pt) | 2020-07-21 |
EP3638229A4 (en) | 2021-03-03 |
WO2018232094A1 (en) | 2018-12-20 |
KR20200028939A (ko) | 2020-03-17 |
AU2018283053B2 (en) | 2022-09-08 |
MX2023004309A (es) | 2023-05-04 |
CA3066164A1 (en) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020000194A2 (es) | Inhibidores de quinasa alk2 que contienen imidazol | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
CO2018008916A2 (es) | Compuestos de benzopirazol y análogos de estos | |
CR20140413A (es) | Inhibidores de serina/treonina cinasa | |
EA201691625A1 (ru) | Ароматические гетероциклические соединения как противовоспалительные соединения | |
AR103828A1 (es) | INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b | |
UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
CO2019006220A2 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos | |
UY37879A (es) | Compuestos de bisamida que activan el sarcómero y sus usos | |
CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. | |
MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
MX2017012295A (es) | Derivados formilados n-heterociclicos como inhibidores de fgfr4. | |
EA201691670A1 (ru) | Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2 | |
CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
CO2018004572A2 (es) | Inhibidores de calicreína plasmática humana | |
CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
UY37331A (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
CY1121909T1 (el) | Παραγωγο του 4-(3-πυραζολυλαμινο)-βενζιμιδαζολιου ως αναστολεας της jak1 για την αγωγη του καρκινου | |
AR104241A1 (es) | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos | |
MX2016013561A (es) | Activadores de herg policiclicos. | |
ECSP23096182A (es) | Inhibidores de alk2 quinasa que contienen imidazol | |
EA201791596A1 (ru) | Пиразоловые соединения |